Eccogene

Privately held: no public share price

Assets

(2 total)
2Total Assets
0Approved
1Phase 3 / Filed
1Phase 1–2 / Early
5Diseases
Quick filter:
Showing 2 of 2 assets
Target & Modality
Phase 3
GLP-1 receptorSmall molecule
ObesityType 2 DiabetesHeart FailureChronic Kidney Disease
Phase 2
Thyroid hormone receptor beta (THRβ)
ObesityMASH / NASH

Upcoming events

(10 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2027 (1)
September 2027 (1)
ECC4703Phase 2Metabolic Dysfunction-associated Steatohepatitis
Est. primary completion 2027-09-15 · NCT07288138 · CT.gov ↗
What to watch
2028 (7)
April 2028 (1)
elecoglipronPhase 3Obesity, Overweight
Est. primary completion 2028-04-06 · NCT07775404 · CT.gov ↗
What to watch
May 2028 (2)
elecoglipronPhase 3Type 2 Diabetes Mellitus
Est. primary completion 2028-05-23 · NCT07662213 · CT.gov ↗
What to watch
elecoglipronPhase 3Type 2 Diabetes Mellitus
Est. primary completion 2028-05-23 · NCT07664553 · CT.gov ↗
What to watch
July 2028 (4)
elecoglipronPhase 3Type 2 Diabetes Mellitus
Est. primary completion 2028-07-05 · NCT07662109 · CT.gov ↗
What to watch
elecoglipronPhase 3Type 2 Diabetes Mellitus, Type 2 Diabetes With Chronic Kidney Disease
Est. primary completion 2028-07-13 · NCT07662135 · CT.gov ↗
What to watch
elecoglipronPhase 3Type 2 Diabetes Mellitus
Est. primary completion 2028-07-14 · NCT07662044 · CT.gov ↗
What to watch
elecoglipronPhase 3Weight Management
Est. primary completion 2028-07-31 · NCT07667803 · CT.gov ↗
What to watch
2029 (1)
September 2029 (1)
elecoglipronPhase 3Heart Failure With Preserved Ejection Fraction (HFpEF), Heart Failure With Mildly Reduced Ejection Fraction (HFmrEF)
Est. primary completion 2029-09-03 · NCT07761117 · CT.gov ↗
What to watch
2030 (1)
October 2030 (1)
elecoglipronPhase 3Chronic Kidney Disease
Est. primary completion 2030-10-04 · NCT07753993 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

June 2026PresentationelecoglipronVISTA Phase IIb results at ADA 2026: dual primary endpoint met

Financial reports

No financial reports recorded.